Wednesday, July 8, 2026

pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX

Protagonist Therapeutics

Protagonist Therapeutics is a pharma organization headquartered in Newark, USA. It trades on NYSE under ticker PTGX. Primary therapeutic focus areas include Polycythemia Vera, Ulcerative Colitis Chronic Moderate, Celiac

7707 Gateway Blvd, Suite 140, Newark, California 94560, US HQ
2006 Founded
153 Employees
Public company Type
PTGX · NYSE Ticker
Company details
Status
Public
HQ
7707 Gateway Blvd, Suite 140, Newark, California 94560, US
Founded
2006
Employees
153
Programs
13
Drugs
5
Patents
33
Clinical program

PN-235

Phase 1 · small molecule · Healthy Volunteers

PN-235 for Healthy Volunteers is a Phase 1 program (small_molecule) at Protagonist Therapeutics, Inc with 1 ClinicalTrials.gov record(s).

← All Protagonist Therapeutics, Inc projects Phase 1 small molecule completed

Internal code PN-235-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Protagonist Therapeutics, Inc
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1

Clinical trials